JPRN-jRCT2080221972未知2 期
Phase 2 Study to Evaluate Safety and Pharmacodynamics of CS-3150 in Type 2 Diabetes Mellitus Patients with Albuminuria
DAIICHISANKYO Co.,Ltd.0 个研究点开始时间: 2012年12月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 30age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •Main Inclusion Criteria;
- •-A diagnosis of Type 2 Diabetes Mellitus with Albuminuria
- •-Male and Female of 30 to 70 years of age
- •-Complication of Hypertension
排除标准
- •Main Exclusion Criteria;
- •-Type 1 Diabetes Mellitus
- •-Patients with known Non-Diabetic Renal Disease
研究者
相似试验
进行中（未招募）
1 期
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursPancreatic ductal adenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2021-002040-78-ESAstraZeneca AB115
进行中（未招募）
1 期
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ402671 in Treatment-naïve Adult Male Patients with Fabry DiseaseFabry diseaseEUCTR2013-005324-41-GBGenzyme Corporation8
进行中（未招募）
1 期
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ402671 in Treatment-naïve Adult Male Patients with Fabry DiseaseFabry diseaseMedDRA version: 17.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-005324-41-CZGenzyme Corporation8
进行中（未招募）
1 期
A Phase 2A Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged =6 to <18 Years With Atopic DermatitisEUCTR2014-003263-37-HURegeneron Pharmaceuticals, Inc.78
进行中（未招募）
不适用
A study to determine the safety and tolerability of REGN668 in patients aged =6 to <18 years with atopic dermatitis (eczema)EUCTR2014-003263-37-PLRegeneron Pharmaceuticals, Inc.80